1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland...
-
Upload
chloe-black -
Category
Documents
-
view
231 -
download
2
Transcript of 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland...
![Page 1: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/1.jpg)
1
Scott Stibitz, Ph.D.
Center for Biologics Evaluation and Research (CBER), FDA
Bethesda, Maryland
FDA Regulation of
Bacterial Vaccines
![Page 2: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/2.jpg)
Types of Bacterial Vaccines
• Live, attenuated: Salmonella Ty21A
• Inactivated: Diphtheria and Tetanus toxoids
• Crude or purified antigens derived from living or killed cells: acellular pertussis antigens, polysaccharides (PS)
• Conjugate vaccines: Hib and pneumococcal PS-Protein conjugate
• Recombinant antigens: (investigational)
• Vectored and DNA vaccines: (investigational)
![Page 3: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/3.jpg)
Licensed biological products, including vaccines, must be:
• Safe
• Pure
• Potent
• Manufactured consistently according to Current Good Manufacturing Practices (CGMPs)
![Page 4: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/4.jpg)
FDA Regulatory Definitions
• Safety (21 CFR 600.3(p)): “…the relative freedom from harmful effect to persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of the product in relation to the condition of the recipient at the time.”
![Page 5: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/5.jpg)
FDA Regulatory Definitions
• Purity (21 CFR 600.3(r)): “…relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the product. Purity includes but is not limited to relative freedom from residual moisture or other volatile substances and pyrogenic substances.”
![Page 6: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/6.jpg)
FDA Regulatory Definitions
• Potency (21 CFR 600.3(s)): “…the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through administration of the product in the manner intended, to effect a given result.”
![Page 7: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/7.jpg)
Vaccine DevelopmentVaccine Development
Pre INDPre IND
DevelopmentDevelopmentof Rationaleof RationaleBased on Based on DiseaseDiseasePathogenesisPathogenesis
Identify Identify Product Product Component(s)Component(s) Antigen(s),Antigen(s), adjuvant, etc.adjuvant, etc.
Development Development ofofManufacturing Manufacturing Process,Process,Preclinical Preclinical StudiesStudies
INDIND
ClinicalClinicalStudies,Studies,Additional Additional Non-clinical Non-clinical Development Development & Studies, & Studies, Scale-up and Scale-up and refinement of refinement of manufacturing manufacturing processprocess
IND = Investigational New Drug applicationIND = Investigational New Drug application
![Page 8: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/8.jpg)
Stages of Vaccine Review and Regulation
Clinical Investigational Plan
Phase 1SafetyImmuno-genicity
Phase 2Immuno-genicitySafetyDose Ranging
Phase 3EfficacySafetyImmuno-genicity
BLA Data to support approval;Inspection
Phase 4InspectionSafetyEfficacyLot Release
BLA SupplementPost-approvalChanges:New IndicationsDosingManufactureEquip./Facilities
IND
IND = Investigational New Drug Application; BLA = Biologics License Application(BLAs analogous to NDAs for Drugs. BLAs & NDAs are marketing applications.)
![Page 9: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/9.jpg)
FDA’s Primary Objectives in Reviewing an IND
• 21 CFR 312.22(a)
• In all phases of the investigation, to assure the safety and rights of subjects
• In Phase 2 and 3, to help assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the drug’s effectiveness and safety
![Page 10: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/10.jpg)
CMC Information for Bacterial Vaccines
Strain construction and/or characterization* Cell banks: methods for manufacture,
characterization* Fermentation conditions* Purification methods Final formulation procedures In-process testing Lot release testing Plan for stability testing
*TSE issues
![Page 11: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/11.jpg)
Lot Release Testing
• Sterility (microbial purity) – absence of bacterial or fungal contaminants
• General safety test - guinea pigs and mice to detect extraneous toxic contaminants
• Identity test - e.g. SDS-PAGE, Western blot, immunologic assay or amino acid analysis
• Purity - e.g. % moisture, SDS-PAGE, HPLC, endotoxin
• Potency - in vivo or in vitro test to assess immunogenicity, antigen content, or chemical composition
• Tests for removal of process contaminants, as applicable
![Page 12: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/12.jpg)
FDA Potency Regulations
• 21 CFR 600.3 (s):– The word potency is interpreted to mean the
specific ability or capacity of the product…to effect a given result.
• 21 CFR 610.10:– Tests for potency shall consist of either in
vitro or in vivo tests, or both, which have been specifically designed for each product so as to indicate its potency…
![Page 13: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/13.jpg)
Product Potency Test
• Ideally, predictive of effective human immune response • Ideally, correlation of a lab assay or animal immune
response with expected human immunological response in dose-dependent manner
• Used to demonstrate that product meets predefined acceptance and/or rejection criteria (lot to lot consistency)
• Critical parameter for product stability
• Examples:– Live attenuated bacteria - colony forming units– Purified antigen - mouse immunogenicity– Purified polysaccharide - size distribution
![Page 14: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/14.jpg)
Vaccine Adjuvants
![Page 15: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/15.jpg)
Vaccine Nonclinical Studies
Product Characterization
Attenuation (Live Organisms)
Inactivation/Reversion
Absence of Adventitious Agents
Pyrogenicity
Potency, Immunogenicity
Challenge/Protection Studies
Toxicity study (novel products)
![Page 16: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/16.jpg)
Nonclinical Safety Studies
• Study design based on intended clinical use• Relevant animal model
• Vaccine immunogenic in chosen species• Non-human primates usually not necessary
• Minimize animal use by combining safety and immunogenicity evaluations
• Evaluation of product-specific concerns
• Developmental toxicity studies (prior to study specifically enrolling pregnant women)
• Safety studies conducted under GLPs
![Page 17: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/17.jpg)
Chlamydia vaccine questions
• How much efficacy must be demonstrated?
• How long must immunity last?
• What about multiple-serotypes?
• Is a correlate of immunity or protection necessary?
• What about possible exacerbation of disease? (severity or incidence)
![Page 18: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/18.jpg)
Possible approaches to exacerbation concerns
• Might be worthwhile establishing unambiguously the existence of the problem
• Animal model of exacerbation would be very helpful
• Establishing an immunological correlate to potential for exacerbation would be helpful
![Page 19: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/19.jpg)
Meetings with FDA (21 CFR 312.47)
Phase 1 Phase 2 Phase 3 License Application
Pre-INDMeeting:ManufacturingProduct Lot ReleaseAnimal safety &immunogenicityPhase 1 protocol
End-of-Phase 2Meeting:Efficacy trial protocol(s)Phase 1/2 dataUpdate:* Product, etc.Assay dataRationale
Pre-BLAMeeting:Clinical datasummary: S & EUpdate:* Product, etc.Outline of BLA
IND = Investigational New Drug ApplicationBLA = Biologics License Application
![Page 20: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/20.jpg)
Available Resources
• CBER/FDA main web site– http://www.fda.gov/cber/
• CBER webpage on submitting an IND – http://www.fda.gov/cber/ind/ind.htm
• CBER FAQs– http://www.fda.gov/cber/faq.htm
• Food and Drug Related Laws– http://www.fda.gov/opacom/laws/
• Code of Federal Regulations (CFR)– http://www.gpoaccess.gov/cfr/index.html
• CBER Guidance Documents– http://www.fda.gov/cber/guidelines.htm
• BSE/TSE issues including estimating risk– http://www.fda.gov/cber/bse/bse.htm
![Page 21: 1 Scott Stibitz, Ph.D. Center for Biologics Evaluation and Research (CBER), FDA Bethesda, Maryland FDA Regulation of Bacterial Vaccines.](https://reader036.fdocuments.net/reader036/viewer/2022062301/56649e295503460f94b16f61/html5/thumbnails/21.jpg)
The beginning?